Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00659126
Other study ID # IRB00002864
Secondary ID NCI-2015-00225SO
Status Terminated
Phase Phase 2
First received
Last updated
Start date November 16, 2006
Est. completion date December 31, 2020

Study information

Verified date August 2023
Source OHSU Knight Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies how well magnetic resonance imaging (MRI) using contrast imaging agent ferumoxytol works in comparison to standard imaging agent gadolinium in measuring tumors in patients undergoing treatment for brain tumors or other tumors that have spread to the brain. Diagnostic procedures, such as MRI, may help find and diagnose disease and find out how far the disease has spread. MRI scans use radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. The contrast imaging agent ferumoxytol consists of small iron particles taken by the blood stream to the brain and to the area of the tumor. It is highly visible on the MRI, and may help visualize the blood flow going through the tumor better than gadolinium can. Using a more sensitive and faster 7 Tesla (7T) magnet MRI in conjunction with a contrast imaging agent may provide a better way to measure tumors than the 3 Tesla (3T) magnet MRI in patients with brain tumors.


Description:

PRIMARY OBJECTIVES: I. To compare quantitative blood brain barrier permeability measurements (derived transfer coefficient [Ktrans]) of a standard gadolinium (Gd) MRI contrast agent at 3T and 7T using dynamic contrast enhancement (DCE) MRI. II. To compare dynamic susceptibility contrast (DSC) based perfusion measures at 3T and 7T. SECONDARY OBJECTIVES: I. To describe the blood brain barrier permeability to ferumoxytol (ferumoxytol non-stoichiometric magnetite) and to a standard gadolinium-based MRI contrast agent using signal intensity changes as described above. II. To describe cerebral blood volume (CBV) measurements obtained using a standard gadolinium MRI contrast agent and ferumoxytol. III. To evaluate tumor microvascularity on susceptibility-weighted images (SWI). IV. To describe the microscopic distribution of ferumoxytol particles in tissue removed from subjects undergoing surgery. OUTLINE: Patients are assigned to 3T or 7T magnet within the subgroups. Patients receive gadolinium intravenously (IV) on day 1 and ferumoxytol non-stoichiometric magnetite IV on day 2. Patients undergo anatomical MRI sequences with 3T or 7T at baseline and on days 1-3. Patients also undergo DSC MRI and DCE MRI on days 1-2. Day 1 and day 2 imaging sessions may be separated by up to 7 days. After completion of study, patients are followed up at approximately 4-6 weeks.


Recruitment information / eligibility

Status Terminated
Enrollment 40
Est. completion date December 31, 2020
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects with radiographically suspected, histologically or cytologically confirmed primary brain tumors or brain metastasis are eligible - Subjects may be enrolled at any point in diagnosis or treatment - Subjects must have had radiographically evaluable or measurable disease with standard magnetic resonance (MR) imaging - Members of all races and ethnic groups will be included - Eastern Cooperative Oncology Group (ECOG) performance status =< 3 (Karnofsky performance status [KPS] >= 30) - Ability to understand and the willingness to sign a written informed consent document, or have a representative able to consent for the subject - Sexually active women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study treatment and for the duration of study treatment; should a female become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately - Subject agrees to complete follow up visit Exclusion Criteria: - Subjects with clinically significant signs of uncal herniation, such as acute pupillary enlargement, rapidly developing motor changes (over hours), or rapidly decreasing level of consciousness - Subjects who have a contraindication for MRI: metal in their bodies (a cardiac pacemaker or other incompatible device), are severely agitated, need monitored anesthesia for scanning, or have an allergy to Gd contrast material - Subjects with known hepatic insufficiency or cirrhosis - History of allergic reactions attributed to compounds of similar chemical or biologic composition to ferumoxytol - Subjects with known or suspected iron overload (genetic hemochromatosis or history of multiple transfusions) - Subjects expecting to undergo surgery between the imaging sessions; subjects may undergo surgery at any time before the first, or after the last imaging session; this exclusion only applies to each study visit (3 day scanning session), and does not apply to the time (at least 3 weeks) between each study visit - Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Pregnant or lactating women are excluded from this study - Inability or unwillingness to undergo the complete series of imaging sessions; inability or unwillingness to complete the one month follow-up - Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible - Subjects with glomerular filtration rate (GFR) < 50 - Subjects with three or more drug allergies from separate drug classes

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
3 Tesla Magnetic Resonance Imaging
Undergo 3T MRI
Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Undergo DCE MRI
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Undergo DSC MRI
Drug:
Ferumoxytol
Given IV
Gadolinium
Given IV
Procedure:
High Field Strength Magnetic Resonance Imaging
Undergo 7T MRI
Susceptibility Weighted Imaging
Undergo SWI

Locations

Country Name City State
United States OHSU Knight Cancer Institute Portland Oregon

Sponsors (3)

Lead Sponsor Collaborator
OHSU Knight Cancer Institute National Cancer Institute (NCI), Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Contrast to Noise Ratio (CNR), in Terms of Normalized Signal Intensity Changes, for T1-weighted MRI Signal at 3T and 7T (Gadolinium [Gd] T1-weighted Magnetic Resonance Imaging [MRI] DCE Data Only) Paired sample t-tests will be used for primary descriptive comparisons. Secondary analyses will use a repeated measures analysis of variance (ANOVA) model to compare 3T and 7T while adjusting for other factors including tumor type, prior therapy, and, potentially, important baseline factors that differ between the subjects assigned to the two field strengths. Normality will be assessed graphically and, if needed, a transformation (e.g. the logarithmic transform) will be applied. Baseline to day 1
Primary CNR, in Terms of Normalized Signal Intensity Changes, for Dynamic Susceptibility Contrast (DSC) MRI Data Sets at 3T and 7T (Gadolinium and Ferumoxytol) A two sample t-test was used for primary descriptive comparisons since CNR was measured on different subjects at 3T and 7T. There were no repeated measures in the resulting data. Given the small sample size, a linear regression was conducted to compare CNR between 3T and 7T only adjusted for Fe dose. No other adjusted analyses were conducted.
CNR was compared between 3T and 7T for both Ferumoxytol and Gadolinum. Ferumoxytol was administered using three injections and CNR was measured after each injection, thus we have three measures of CNR (Fe1CNR, Fe2CNR and Fe3CNR).
Day 1 to day 2
Secondary Relevant Dynamic MRI (Dynamic Contrast Enhancement [DCE] and DSC) Signal Intensity Changes for Permeability and Perfusion Mixed model repeated measures ANOVAs will be fit. Factors will include imaging agent (Gd or ferumoxytol) and field strength (3T and 7T). Each subject will contribute one measure for each combination of imaging agent and field strength (4 measures total). Day 1 to day 2
Secondary Change in Cerebral Blood Volume (CBV) Measurements, Quantified Using DSC Techniques Blood volumes will be compared using repeated measures ANOVA to compare the imaging agents. Day 1 to day 2
Secondary Change in Tumor Microvascularity on Susceptibility-weighted Images (SWI) Before and After Ferumoxytol Analysis will also include covariates of prior therapy. For the comparisons between treated and untreated subjects, means and confidence intervals will be estimated for each group for the perfusion and permeability measures and for the baseline characteristics. Day 1 to day 2
Secondary Presence of Iron Staining The pathology will be analyzed qualitatively for the presence of iron staining. The amount and localization of the staining will be assessed, with attention paid to whether the tumor cells themselves or reactive cells in and around the tumor demonstrate iron uptake. At time of surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04062305 - nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex N/A
Recruiting NCT05388877 - E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma Phase 1
Completed NCT03071913 - Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery
Active, not recruiting NCT02595905 - Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Phase 2
Recruiting NCT03270059 - Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System Phase 2
Terminated NCT00096265 - Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer Phase 3
Completed NCT02858869 - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Phase 1
Active, not recruiting NCT04250545 - Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer Phase 1
Recruiting NCT05341349 - Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases Phase 1
Active, not recruiting NCT04114981 - Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease Phase 3
Recruiting NCT03741673 - Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases Phase 3
Completed NCT03680144 - Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases N/A
Completed NCT02167204 - 18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors N/A
Recruiting NCT03750227 - Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors Phase 3
Recruiting NCT03418961 - S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer Phase 3
Active, not recruiting NCT02993146 - Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases Phase 1
Not yet recruiting NCT06328686 - Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases Early Phase 1
Active, not recruiting NCT02589522 - Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors Phase 1
Recruiting NCT04804644 - Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability Phase 3
Withdrawn NCT03868423 - Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers Phase 2